#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10956	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2120	508.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	622	C	598	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10956	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2120	508.9	0	HET	.	.	.	C207T	.	207	207	C	433	433	C	624	C,T	470,121	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20472	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3630	559.5	0	.	n	.	0	T695C	SNP	695	695	T	1059	1059	C	626	C	598	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20472	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3630	559.5	0	.	n	.	0	A1638G	SNP	1638	1638	A	2002	2002	G	610	G,A	578,11	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20472	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3630	559.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2335	2335	C	614	C	591	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20472	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3630	559.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2409	2409	A	654	A,G,C	635,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	20472	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3630	559.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2961	2961	C	624	C	602	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1212	folP	855	855	100.0	folP.l15.c4.ctg.1	1625	73.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1047	1049	AGC	113;111;112	A;G,C;C	109;107,1;107	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3816	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3473	108.7	1	SNP	p	S91F	1	.	.	271	273	TTC	619	621	TTC	128;128;130	T;T;C	125;124;126	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3816	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3473	108.7	1	SNP	p	G95N	0	.	.	283	285	GGC	631	633	GGC	130;133;132	G;G;C	127;128;127	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3816	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3473	108.7	1	SNP	p	D95G	1	.	.	283	285	GGC	631	633	GGC	130;133;132	G;G;C	127;128;127	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1098	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1337	80.8	1	SNP	p	G45D	0	.	.	133	135	GGC	525	527	GGC	128;129;128	G;G;C,T	119;121;120,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	594	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	946	62.2	0	.	n	.	0	A197.	DEL	197	197	A	544	544	A	144	A	141	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3012	122.9	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	135;134;135	G;A;C	130;126;131	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3012	122.9	1	SNP	p	R87I	0	.	.	259	261	CGT	581	583	CGT	134;132;132	C;G;T	127;127;127	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3012	122.9	1	SNP	p	S87R	1	.	.	259	261	CGT	581	583	CGT	134;132;132	C;G;T	127;127;127	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3012	122.9	1	SNP	p	R87W	0	.	.	259	261	CGT	581	583	CGT	134;132;132	C;G;T	127;127;127	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3736	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3012	122.9	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	134;134;133	T;C;C	130;129;127	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2720	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2581	104.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1522	1524	GGC	127;127;127	G;G;C	122;124;121	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	A311V	0	.	.	931	933	GCC	1268	1270	GCC	151;149;151	G;C;C	144;142;147	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	I312M	1	.	.	934	936	ATG	1271	1273	ATG	151;150;152	A;T;G	145;144;146	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	T316P	0	.	.	946	948	ACC	1283	1285	ACC	159;161;161	A;C;C	148;155;155	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	V316T	1	.	.	946	948	ACC	1283	1285	ACC	159;161;161	A;C;C	148;155;155	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1784	1786	ACC	142;142;143	A,G;C;C	129,1;137;140	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1838	1840	GCG	159;159;157	G;C;G	154;151;149	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1838	1840	GCG	159;159;157	G;C;G	154;151;149	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1961	1963	GGT	119;119;119	G,A;G;T,C	112,2;115;113,2	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1970	1972	AGC	111;111;112	A,G;G;C	106,2;109;109	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3004	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2361	125.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1988	1990	CCG	90;92;90	C,G;C,G;G	82,1;85,1;80	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4596	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3116	146.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1664	1666	CCG	158;161;158	C;C;G	142;156;146	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1868	porA	1146	1146	99.91	porA.l6.c30.ctg.1	1878	97.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	611	611	C	129	C	117	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2180	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1573	136.6	1	SNP	p	G120K	1	.	.	358	360	AAG	607	609	AAG	166;167;172	A,C;A;G	157,1;164;163	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2180	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1573	136.6	1	SNP	p	A121N	1	.	.	361	363	AAC	610	612	AAC	173;172;171	A,G;A;C,A	167,1;166;166,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2180	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1573	136.6	1	SNP	p	N121D	0	.	.	361	363	AAC	610	612	AAC	173;172;171	A,G;A;C,A	167,1;166;166,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7674	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4780	158.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	958	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1001	94.3	1	SNP	p	V57M	1	.	.	169	171	ATG	467	469	ATG	192;192;195	A;T;G	187;186;191	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
